drugset / Trial / NCT00520000
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors
Phase 1
Completed
47 enrolled
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving paclitaxel albumin-stabilized nanoparticle formulation together with carboplatin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects, the best way to give, and the best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with carboplatin in treating patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2004-12
- Primary completion
- 2006-05
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abraxane | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Abraxane | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Abraxane | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Abraxane | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Abraxane | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Abraxane | Small molecule | 340 mg/m2 | Intravenous |
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |